CJC-1295

CJC-1295 is a synthetic analog of Growth HormoneReleasing Hormone (GHRH) designed to enhance the release of growth hormone (GH) from the pituitary gland. It exists in two forms: CJC-1295 without DAC (Drug Affinity Complex) and CJC-1295 with DAC. The presence of DAC extends the half-life of the peptide, affecting its release and duration of action on GH secretion.


Mechanism of Action

CJC-1295 without DAC mimics the physiological action of GHRH, binding to the GHRH receptors on the pituitary gland to stimulate the release of GH. Its effects are more immediate but with a shorter duration of action, requiring more frequent dosing.

CJC-1295 with DAC utilizes the Drug Affinity Complex technology to extend the peptide’s half-life. This form continuously stimulates the GH release over an extended period, typically up to a week, mimicking the natural pulsatile release of GH without significantly altering its natural pattern.


Benefits and Uses

Both forms of CJC-1295 offer a range of benefits, including:

Improved Sleep Quality: Some users report better sleep patterns, which is crucial for recovery and overall health.

Strengthened Immune System: GH has been known to enhance the immune response.

CJC-1295 without DAC is often preferred for more controlled GH release patterns, while CJC-1295 with DAC is chosen for its convenience of less frequent dosing and sustained GH levels.


Dosage and Cycle Guidelines

For CJC-1295 without DAC, a common dosage is 100-200 mcg per injection, administered 2-3 times daily. This regimen maximizes the natural pulsatile pattern of GH release.

For CJC-1295 with DAC, dosages typically range from 2 mg once weekly, providing a steady release of GH. The extended half-life of DAC reduces the need for frequent dosing.

Cycle length can vary based on individual goals and response, with 8-12 weeks being common. It is followed by a break or evaluation period to assess benefits and adjust dosages if necessary.


Potential Side Effects

Water Retention: Some users experience water retention, particularly around the ankles and face.

Injection Site Reactions: Redness, itching, or soreness at the injection site.

Headaches and Dizziness: Mild headaches or dizziness may occur shortly after injection.

Hypoglycemia: Rarely, a drop in blood sugar levels may cause feelings of lightheadedness or weakness.

Carpal Tunnel Syndrome: Increased GH levels can lead to symptoms of carpal tunnel in susceptible individuals.

The choice between CJC-1295 without DAC and with DAC often comes down to preferences regarding injection frequency and desired GH release pattern. Both peptides have a strong safety profile. However, as with all supplements or drugs, monitoring for side effects and consulting the forum experts before starting a new regimen is advisable